Compare ResMed Inc. (RMD) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Skyworks Solutions Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Skyworks Solutions Inc trades at $76.14 (market cap $11.34B). The key difference: ResMed Inc. is far larger — about 2.8× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| RMD | SWKS | |
|---|---|---|
Market Cap | $31.89B | $11.34B |
Sector | Health | Technology |
52-Week High | $283.28 | $83.40 |
52-Week Low | $182.82 | $52.50 |
Enterprise Value | $31.24B | $11.22B |
Dividend Yield | 1.19% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Skyworks Solutions (SWKS) trades at $75.38, up 1.84% with bullish technical signals from moving averages. The stock shows strong earnings momentum with three consecutive quarterly beats, though revenue has declined from $5.5B in 2022 to $4.1B in 2025. Analyst consensus is positive with 58% buy ratings, though the current price exceeds the $66.44 consensus target. Recent institutional buying and conference participation indicate ongoing investor interest despite margin compression and revenue headwinds.
The outlook remains cautiously optimistic with AI data center growth providing upside potential, but investors face risks from declining profitability margins and ongoing revenue contraction. The stock's elevated P/E ratio of 39.06 requires continued earnings growth justification, while technical indicators show potential resistance near $76-77 levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
